vs
Side-by-side financial comparison of Merck & Co. (MRK) and XP Inc. (XP). Click either name above to swap in a different company.
Merck & Co. is the larger business by last-quarter revenue ($16.3B vs $13.5B, roughly 1.2× XP Inc.). Merck & Co. runs the higher net margin — 0.9% vs 0.0%, a 0.9% gap on every dollar of revenue.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
XP Inc. is a Brazilian investment management company. The company offers fixed income, equities, investment funds, and private pension products, as well as offers wealth management and other financial services. XP serves customers in Brazil and has offices in São Paulo, Rio de Janeiro, New York, Miami, London and Geneva.
MRK vs XP — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.3B | $13.5B |
| Net Profit | $141.0M | $22.0K |
| Gross Margin | 74.2% | — |
| Operating Margin | — | 1.1% |
| Net Margin | 0.9% | 0.0% |
| Revenue YoY | 4.9% | — |
| Net Profit YoY | -9.5% | — |
| EPS (diluted) | — | $536884.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $16.3B | — | ||
| Q4 25 | $16.4B | — | ||
| Q3 25 | $17.3B | $13.5B | ||
| Q2 25 | $15.8B | $8.8B | ||
| Q1 25 | $15.5B | $4.3B | ||
| Q4 24 | $15.6B | — | ||
| Q3 24 | $16.7B | $12.6B | ||
| Q2 24 | $16.1B | $8.3B |
| Q1 26 | $141.0M | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $5.8B | $22.0K | ||
| Q2 25 | $4.4B | $22.0K | ||
| Q1 25 | $5.1B | $22.0K | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.2B | $21.0K | ||
| Q2 24 | $5.5B | $21.0K |
| Q1 26 | 74.2% | — | ||
| Q4 25 | 66.2% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.0% | — | ||
| Q4 24 | 75.5% | — | ||
| Q3 24 | 75.5% | — | ||
| Q2 24 | 76.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 20.9% | — | ||
| Q3 25 | 39.0% | 1.1% | ||
| Q2 25 | 31.6% | 1.0% | ||
| Q1 25 | 38.0% | 1.1% | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 24.6% | 1.0% | ||
| Q2 24 | 37.3% | 0.9% |
| Q1 26 | 0.9% | — | ||
| Q4 25 | 18.1% | — | ||
| Q3 25 | 33.5% | 0.0% | ||
| Q2 25 | 28.0% | 0.0% | ||
| Q1 25 | 32.7% | 0.0% | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 19.0% | 0.0% | ||
| Q2 24 | 33.9% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | $1.19 | — | ||
| Q3 25 | $2.32 | $536884.00 | ||
| Q2 25 | $1.76 | $537811.00 | ||
| Q1 25 | $2.01 | $539533.00 | ||
| Q4 24 | $1.49 | — | ||
| Q3 24 | $1.24 | $550958.00 | ||
| Q2 24 | $2.14 | $554030.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $20.0B |
| Total Assets | — | $347.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $14.6B | — | ||
| Q3 25 | $18.2B | — | ||
| Q2 25 | $8.6B | — | ||
| Q1 25 | $9.2B | — | ||
| Q4 24 | $13.7B | — | ||
| Q3 24 | $14.6B | — | ||
| Q2 24 | $11.4B | — |
| Q1 26 | — | — | ||
| Q4 25 | $52.6B | — | ||
| Q3 25 | $51.9B | $20.0B | ||
| Q2 25 | $49.0B | $20.0B | ||
| Q1 25 | $48.3B | $20.0B | ||
| Q4 24 | $46.3B | — | ||
| Q3 24 | $44.5B | $19.5B | ||
| Q2 24 | $43.6B | $19.5B |
| Q1 26 | — | — | ||
| Q4 25 | $136.9B | — | ||
| Q3 25 | $129.5B | $347.5B | ||
| Q2 25 | $117.5B | $347.5B | ||
| Q1 25 | $115.1B | $347.5B | ||
| Q4 24 | $117.1B | — | ||
| Q3 24 | $117.5B | $249.0B | ||
| Q2 24 | $112.6B | $249.0B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
